Vaccine adjuvants for infectious disease in the clinic
Adjuvants, materials added to vaccines to enhance the resulting immune response, are
important components of vaccination that are many times overlooked. While vaccines …
important components of vaccination that are many times overlooked. While vaccines …
Enhanced neutralization of SARS-CoV-2 variant BA. 2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster
X Wang, S Jiang, W Ma, X Li, K Wei, F Xie, C Zhao… - Cell host & …, 2024 - cell.com
Summary Emerging SARS-CoV-2 sub-lineages like XBB. 1.5, XBB. 1.16, EG. 5, HK. 3 (FLip),
and XBB. 2.3 and the variant BA. 2.86 have recently been identified. Understanding the …
and XBB. 2.3 and the variant BA. 2.86 have recently been identified. Understanding the …
COVID-19 vaccines: where did we stand at the end of 2023?
K Lundstrom - Viruses, 2024 - mdpi.com
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
Heterologous versus homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical …
MA Asante, ME Michelsen, MM Balakumar… - BMC medicine, 2024 - Springer
Background To combat coronavirus disease 2019 (COVID-19), booster vaccination
strategies are important. However, the optimal administration of booster vaccine platforms …
strategies are important. However, the optimal administration of booster vaccine platforms …
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG. 5 Subvaraint: A Phase 2 Trial
J Tang, Q Xu, C Zhu, K Xuan, T Li, Q Li, X Pang, Z Zha… - Vaccines, 2024 - mdpi.com
The Omicron EG. 5 lineage of SARS-CoV-2 is currently on a trajectory to become the
dominant strain. This phase 2 study aims to evaluate the immunogenicity of SCTV01E-2, a …
dominant strain. This phase 2 study aims to evaluate the immunogenicity of SCTV01E-2, a …
Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
A Hromić-Jahjefendić, K Lundstrom, M Adilović… - Autoimmunity …, 2023 - Elsevier
The complicated relationships between autoimmunity, COVID-19, and COVID-19
vaccinations are described, giving insight into their intricacies. Antinuclear antibodies (ANA) …
vaccinations are described, giving insight into their intricacies. Antinuclear antibodies (ANA) …
A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations
G Qian, C Gao, M Zhang, Y Chen, L Xie - Vaccines, 2024 - mdpi.com
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
resulting in the COVID-19 pandemic, has profoundly impacted global healthcare systems …
resulting in the COVID-19 pandemic, has profoundly impacted global healthcare systems …
COVID-19 Vaccines: Where Do We Stand at the End of 2023?
K Lundstrom - 2024 - preprints.org
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
COVID-19 Vaccines: Where Did We Stand at the End of 2023? Viruses 2024, 16, 203
K Lundstrom - 2024 - europepmc.org
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …